Little Biotech on the Prairie  by Wolfson, Wendy
Chemistry & Biology
InnovationsLittle Biotech on the Prairie
Wendy Wolfson
DOI 10.1016/j.chembiol.2007.09.004Fargo, North Dakota, has a lot of hori-
zontal space. In adjoining Moorhead,
Minnesota, is a Viking ship that was
built by a junior high school guidance
counselor and sailed to Norway and
back by family members. In a similar
can-do spirit, Mike Chambers, co-
founder of Aldevron (www.aldevron.
com), thought North Dakota was a
fine place to set up a plasmid farming
operation.
While entrepreneurs like Chambers
provebiotech can sprout up anywhere,
theMidwest still lacks the venture cap-
ital that lubricates places like Boston or
the Bay Area/San Diego. Biotechs out-
side established clusters may appear
more like service providers, as theyin partnership with one of its clients
as well as a high throughput vaccine
platform with Redwood City, Cali-
fornia-basedMaxygen (www.maxygen.
com). ‘‘In 2003, we made the world’s
first DNA vaccine to be used outside
of a trial setting,’’ said Chambers. ‘‘It
was used to immunize the California
condor against West Nile virus.’’ There
are a few other biotechs in Fargo now,
funded by angel investors. ‘‘When we
started out Aldevron, the investment
committee wasn’t attuned to high
tech.’’ Chambers noted. ‘‘But now
people successful in the manufacturing
sector are willing to fund high risk
ventures.’’have to generate revenue to support
their R&D. Although states are offering
incentives to develop local biotech
clusters, how big nascent companies
can growbefore they have to seek their
fortunes elsewhere remains an issue.
Pharma Farming
Chambers, a North Dakota native, and
John Ballantyne, a New Zealander and
fellow science student at North Dakota
State University, founded Aldevron
‘‘with creative use of credit cards’’ in
1998. The two entrepreneurs at first in-
cubated the company in lab space
from NDSU while bootstrapping its
development by contract manufac-
turing DNA plasmids, proteins, and an-
tibodies for biotech companies. Aldev-
ron now totals 50 people, including
Genovac, a German company ac-
quired in 2004. The company plows
its profits back into internal develop-
ment projects including a therapeutic
vaccine for lung cancer developed
The Treachery of Distance
According to Dan Broderick, partner at
Prolog Ventures, a St. Louis, Missouri,
venture capital firm, every biotech job
creates a multiplier effect of 3.1 other
jobs. ‘‘The quality of the deals is high
right now,’’ says Broderick. ‘‘What
you need is technology with a market,
talent, and capital. Those three things
are in the Midwest. We are a little light
in entrepreneurial or C level talent. We
are looking for people who want to
come home.’’
According to Broderick, costs are
low compared to the coasts. Labora-
tory space rents in Wisconsin for $25
a square foot versus Boston’s $45
and New York’s $66. A lab tech in Wis-
consin can be hired for $40,000 and
senior scientists in the $60,000 range.
‘‘The thing we need to deal with in
the Midwest is the treachery of dis-
tance,’’ Broderick said. ‘‘Most inno-
vation and commercialization takes
place in urban areas.’’
The Midwest, formerly considered flyover country, is getting
an increasing amount of attention and investment from East
and West Coast venture capitalists.Chemistry & Biology 14, September 2007 ªMadison, Wisconsin, is the home of
the Wisconsin Alumni Research Fund
(WARF), which commercializes the
research from the University of Wis-
consin. Biotech development is also
encouraged by such entities as the
State of Wisconsin Investment Board
and several angel investor networks.
Sister city Milwaukee has GE Health-
care and the Medical College of
Wisconsin. ‘‘GE Healthcare brings in
world-class people, and sometimes
those world-class people want to
leave GE and do other things,’’ says
Teresa Esser, managing director of
Silicon Pastures, a Milwaukee-based
angel network. ‘‘They come to me
with their resume. GE doesn’t acquire
companies under $100 million. We
are trying to bridge that gap.’’
A Silicon Pastures investment is
Madison-based NeoClone Biotechno-
logy International (www.neoclone.
com), which makes monoclonal anti-
bodies (mAbs) for research and diag-
nostics using a retrovirus and immortal-
ized antibody lines instead of the
standard hybridoma fusions. The now
ten person company was founded in
1999 by a couple of University of
Wisconsin-Madby graduates, Deven
McGlenn and Richard Burgess, Ph.D,
and licensedmAbsproduction technol-
ogy from WARF. NeoClone has cus-
tomers in over 30 countries and antici-
pates total sales north of $1.2 million.
‘‘The biotech community has a great
deal of influence because, relatively
speaking, it is a major industry here,’’
said McGlenn. Ten years ago, it was
difficult to recruit skilled labor, but
since then Madison has experienced
a number of biotech financial suc-
cesses (such as NimbleGen Systems,
Inc., a maker of high-density DNA mi-
croarrays that was acquired by Roche
for $272.5 million, and TomoTherapy,
Inc., which makes imaging and radi-
ation treatment systems for cancer
and raised $222 million in an IPO in
May). Major players such as Promega2007 Elsevier Ltd All rights reserved 969
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and Invitrogen are locating there. ‘‘In
terms of research institutions, we really
don’t lack,’’ said McGlenn. ‘‘WARF
has huge experience in licensing.’’
But lack of venture capital and experi-
enced management are persistent
concerns.
Take your Vitamins
Madison-basedDeltanoid Pharmaceu-
ticals (www.deltanoid.com) develops
treatments based on vitamin D analogs
forosteoporosis, renalosteodystrophy,
psoriasis, and other diseases. The
company was cofounded by Hector
DeLuca, the Harry Steenbock Re-
search Professor of Biochemistry at
the University of Wisconsin-Madison,
and Dr. Margaret Clagett-Dame, his
wife. DeLuca has generated patents
prolifically in the course of five decades
of research on vitamins A and D: over
150 in the U.S. and more than 1000
worldwide, producing more than $150
million for WARF in licensing fees. He
was involved in developing eight drugs,
including Alfarol, Zemplar, Rocaltrol,
and the eponymous Hectorol, which
exceeded $5 billion in pharmaceutical
sales.
DeLuca had existing connections
with pharma companies, a long-term
relationship with WARF through his
own work, and good enough data in
animals to get venture capital invest-
ment for Deltanoid, led by Dan Broder-
ick (formerly at MasonWells) as well as
Venture Investors, LLC. In 2004, Delta-
noid signed collaborations with Abbott
Laboratories to develop Vitamin D
Receptor Activators (VDRAs) for the
treatment of kidney disease and li-
censed to Pfizer its lead compound
2MD [2-methylene-19-nor-20(S)-1 al-
pha, 25-dihydroxyvitamin D 3] to treat
postmenopausal osteoporosis for
$42.5 million in upfront and milestone
payments. But Pfizer abandoned the
collaboration in the following year. Del-
tanoid decided to continue on its own
and is recruiting patients for the phase
II trials. Now the company is going
back to investors for a second round
of funding.
Fortifying Rat Chow
Vitamin D hormone as well as parathy-
roid hormone and calcitonin regulate970 Chemistry & Biology 14, Septemberthe body’s calcium and phosphorus
levels. At too high a dose, vitamin D
is toxic. But if it is lacking, the body
cannot absorb enough calcium and
phosphorus from food for bone build-
ing. In children, vitamin D deficiency
causes rickets; in adults, it causes
osteoporosis.
While the effects of vitamin defi-
ciencies were known for centuries,
the puzzle of how micronutrients
worked was put together incremen-
tally by teams of scientists around
the world. In 1913, Harry Steenbock,
(who also founded WARF) and E.B.
Hart made a link between sun expo-
sure and rickets when they discovered
that a herd of lactating goats kept
inside lost bone mass, compared to
their brethren kept outdoors. In the
1920s, Steenbock and others followed
up with experiments that showed irra-
diating rat chow prevented rickets in
animals. DeLuca, one of Steenbock’s
students, led a team at the University
of Wisconsin that isolated the active
hormone derived from vitamin D,
1,25-hydroxyvitamin D3, which is pro-
duced in sequence by the liver and
kidney. Vitamin D is carried in the
blood by proteins. In the early 1990s,
DeLuca’s lab also established that
vitamin D could affect the immune
system.
‘‘There are two difficult problems we
are trying to solve,’’ said DeLuca. ‘‘We
are trying to bring out a vitamin D
compound that has bone-building ac-
tivity.’’ Osteoporosis treatments cur-
rently on the market mineralize bone
but have no anabolic effects. Delta-
noid is also trying to use a vitamin D
analog to treat autoimmune diseases
such as multiple sclerosis and lupus
and is conducting research on how
vitamin D compounds inhibit cancer
both in vitro and in vivo. ‘‘In addition,
we are always trying to improve drugs
we have out there’’ said DeLuca. De-
Luca’s discoveries had spurred the
formation of two prior companies:
Bone Care International, whose inject-
able drug Hectorol (Doxercalciferol),
which prevents secondary hyperpara-
thyroidism (overproduction of parathy-
roid hormone associated with chronic
kidney disease), was bought by Gen-
zyme in 2005; and Tetrionics, which
manufactured complex active phar-2007 ª2007 Elsevier Ltd All rights reservedmaceutical ingredients and intermedi-
ates, bought by Sigma Aldrich. Delta-
noid is also developing a successor
to Zemplar, produced by Abbott Labo-
ratories, another vitamin D analog to
treat secondary hyperparathyroidism
in kidney dialysis patients that won’t
raise blood calcium levels.
‘‘We have to investigate why blood
calcium goes up,’’ said DeLuca. ‘‘And
what is themolecular basis of suppres-
sion of autoimmune function. It does
something to the immune system that
suppresses the cells that chew up their
own tissue. It is not simply being an im-
mune suppressant. We are targeting
what is going wrong in autoimmune
therapy.’’ Raised blood calcium cal-
cifies tissues in the kidneys, heart,
and cardiovascular systems. ‘‘If we
find an analog that does what it does
in the immunesystemand that doesn’t,
at doses required, raise blood calcium,
then we are golden.’’ DeLuca said.
Deltanoid also has a topical com-
pound, becocalcidiol, a vitamin D
analog for treatment of psoriasis, subli-
censed originally to QuatRx Pharma-
ceuticals. In addition,Deltanoid iswork-
ing on a preclinical compound that
controls blood phosphorus in dialysis
patients to compete with Genzyme’s
Renagel, which prevents phosphates
from being absorbed from the diet.
Knitting It All Together
The Midwest, formerly considered fly-
over country, is getting an increasing
amount of attention and investment
from East and West Coast venture
capitalists. So far in 2007, Ohio com-
panies received $244.3 million in
healthcare investment. Minnesota,
a traditional center of medical devices,
garnered $126 million, and Wisconsin
$16 million. According to Baiju Shah,
president of Cleveland’s Bioenter-
prise (www.bioenterprise.com), the
Midwest generates $8 billion of na-
tional, peer-reviewed NIH research,
but research institutions need to step
up their rate of technology transfer if
they want to commercialize their
research. To combat the paucity of
venture capital, the states are kicking
in funding, such as Ohio’s $1.6 billion
Third Frontier Fund and Michigan’s
$2.1 billion 21st Century Jobs Fund.
Shah cautions that states get in trouble
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in companies, as the temptation is to
make politically driven decisions.
Awards in Ohio go through peer review
by the National Academy of Sciences
and then evaluation by venture capital-
ists from outside Ohio.
Shah cites Copernicus Therapeutics
(www.cgsys.com),which isdevelopinga cure for cystic fibrosis, and Athersys
(www.athersys.com), a Cleveland bio-
tech and stem cell company that is go-
ing public through a reverse merger,
both of which have benefited from
state support in their development. ‘‘It
is too early to declare victory.’’ Shah
said. ‘‘We have notable exits in the
Midwest, such as Esperion Therapeu-Chemistry & Biology 14, September 2007 ªtics in Ann Arbor, which was sold to
Pfizer for $1.3 billion after having
gone public, but we still have a few bio-
tech companies leaving the Midwest
for late-stage development.’’
Wendy Wolfson (wendywolfson@nasw.org) is
a northern California based science and
technology writer.2007 Elsevier Ltd All rights reserved 971
